Re: GlaxoKline to Launch 5 Major Vaccines

[Guest guest]

I thought Frist said these firms had to be dragged kicking and

screaming to make vaccines in the future due to low profits and high

litigation. Does not look like that to me ... imagine that.

> Full story:

> http://www.forbes.com/home/feeds/ap/2005/06/30/ap2118074.html

> or http://tinyurl.com/9vvpk

>

>

> Associated Press

> GlaxoKline to Launch 5 Major Vaccines

> 06.30.2005, 08:47 AM

>

> British drug maker GlaxoKline PLC said Thursday that it has

more

> than 20 vaccines in clinical development, with five major launches

> planned in the next five years.

>

> The company said it will launch Cervarix for the prevention of HPV

> which causes cervical cancer, Rotarix for rotavirus gastroenteritis,

> Streptorix for pneumococcal disease, an improved flu vaccine and

> Hib-MenCY vaccine combinations against meningitis.

>

> These five products will enter markets that have the potential to

> reach a total market value of $11 billion to $18 billion by 2010,

> Glaxo said.

>

> The company estimates that cumulatively, up to 80 million women

could

> be vaccinated by 2010 for protection against cervical cancer, and

the

> cervical cancer vaccine market could be valued at $4 billion to $7

> billion per year by 2010. Regulatory filings of Cervarix will take

> place in Europe in the first half of 2006, and in international

> markets during 2006. Discussions on filing with the Food and Drug

> Administration are ongoing in the U.S., where the vaccine has been

> granted " fast track " status.

>

> Glaxo said the launch of its new pediatric vaccines, combined with

its

> existing portfolio, will give the company a full range of products

to

> meet all infant vaccination schedules in all major markets within

the

> first six months of life.

>

> Glaxo estimates that the global market for rotavirus vaccines could

be

> valued at $1.8 billion to $2.4 billion by 2010. GSK has submitted

> regulatory filings for Rotarix in Europe and 50 other markets, and

> Rotarix has now been approved in 7 markets, including Mexico.

> Discussions on the U.S. filing are ongoing with the FDA.

>

> Glaxo also said it plans to double its Fluarix manufacturing

capacity

> to 80 million doses annually by 2008, is developing an improved flu

> vaccine using a unique adjuvant. The drug maker will develop a new

> cell culture manufacturing process by 2010 to further boost

production

> capacity.

>

> Glaxo estimates that the influenza market could more than double

from

> its current value to $2.9 billion to $3.7 billion in 2010. Fluarix

is

> licensed in 102 countries with 2004 sales of $144 million, and the

> company filed Fluarix with the FDA in May in time to be available

for

> the 2005 to 2006 flu season, if it is approved.

>

> Large Phase III trials of the improved flu vaccine are due to start

in

> 2006, and regulatory filings will take place in the U.S., Europe and

> international markets in 2008, the company said.

>

> GlaxoKline Biologicals, the company's vaccine manufacturing

unit,

> is located in Rixensart, Belgium and posted 2004 sales of nearly $2

> billion. In 2004, GSK Biologicals distributed more than 1.5 billion

> doses of vaccines to 168 countries in both the developed and

> developing world. About 140 million of the doses delivered last year

> were combined pediatric vaccines that protect children against a

> minimum of three and up to six diseases in one vaccine.

>

>

[Guest guest]

Let us contemplate the evenues enhanced by vaccine-related pathologies -

eg, via the CDC (1999, ie, its pre-fudged data) and as confirmed by

Geier and Geier, ADHD, tics, sleep disorders, and autism were among the

syndromes associated with thimerosal injections. Everywhere we look,

there are huge financial incentives for allowing toxins into the

environment and for injecting them directly into humans, and the biggest

financial rewards come from selling OTCs and pharmaceuticals for masking

the symptoms. More vaccinations will lead to more injected toxins, thus

to more adverse pathologies that generate revenue for pharmcos.

Perhaps - when frustrated about the costs of trying to heal an autistic

child - a parent would feel bit of sympathy for the pharmco CEOs whose

job includes delivering as much money as possible into the accounts of

the individuals and families who are the various pharmcos' primary

stockholders.

Jackie Hines wrote:

>Full story:

>http://www.forbes.com/home/feeds/ap/2005/06/30/ap2118074.html

>or http://tinyurl.com/9vvpk

>

>

>Associated Press

>GlaxoKline to Launch 5 Major Vaccines

>06.30.2005, 08:47 AM

>

>British drug maker GlaxoKline PLC said Thursday that it has more

>than 20 vaccines in clinical development, with five major launches

>planned in the next five years.

>

>The company said it will launch Cervarix for the prevention of HPV

>which causes cervical cancer, Rotarix for rotavirus gastroenteritis,

>Streptorix for pneumococcal disease, an improved flu vaccine and

>Hib-MenCY vaccine combinations against meningitis.

>

>These five products will enter markets that have the potential to

>reach a total market value of $11 billion to $18 billion by 2010,

>Glaxo said.

>

>The company estimates that cumulatively, up to 80 million women could

>be vaccinated by 2010 for protection against cervical cancer, and the

>cervical cancer vaccine market could be valued at $4 billion to $7

>billion per year by 2010. Regulatory filings of Cervarix will take

>place in Europe in the first half of 2006, and in international

>markets during 2006. Discussions on filing with the Food and Drug

>Administration are ongoing in the U.S., where the vaccine has been

>granted " fast track " status.

>

>Glaxo said the launch of its new pediatric vaccines, combined with its

>existing portfolio, will give the company a full range of products to

>meet all infant vaccination schedules in all major markets within the

>first six months of life.

>

>Glaxo estimates that the global market for rotavirus vaccines could be

>valued at $1.8 billion to $2.4 billion by 2010. GSK has submitted

>regulatory filings for Rotarix in Europe and 50 other markets, and

>Rotarix has now been approved in 7 markets, including Mexico.

>Discussions on the U.S. filing are ongoing with the FDA.

>

>Glaxo also said it plans to double its Fluarix manufacturing capacity

>to 80 million doses annually by 2008, is developing an improved flu

>vaccine using a unique adjuvant. The drug maker will develop a new

>cell culture manufacturing process by 2010 to further boost production

>capacity.

>

>Glaxo estimates that the influenza market could more than double from

>its current value to $2.9 billion to $3.7 billion in 2010. Fluarix is

>licensed in 102 countries with 2004 sales of $144 million, and the

>company filed Fluarix with the FDA in May in time to be available for

>the 2005 to 2006 flu season, if it is approved.

>

>Large Phase III trials of the improved flu vaccine are due to start in

>2006, and regulatory filings will take place in the U.S., Europe and

>international markets in 2008, the company said.

>

>GlaxoKline Biologicals, the company's vaccine manufacturing unit,

>is located in Rixensart, Belgium and posted 2004 sales of nearly $2

>billion. In 2004, GSK Biologicals distributed more than 1.5 billion

>doses of vaccines to 168 countries in both the developed and

>developing world. About 140 million of the doses delivered last year

>were combined pediatric vaccines that protect children against a

>minimum of three and up to six diseases in one vaccine.

>

>

>

>

>

[Guest guest]

Notice what the primary thru$t of thi$ article i$ !!!!!!

GlaxoKline to Launch 5 Major Vaccines

> http://tinyurl.com/9vvpk

>

> ssociated Press

> GlaxoKline to Launch 5 Major Vaccines

> 06.30.2005, 08:47 AM

>

> British drug maker GlaxoKline PLC said Thursday that it has more

> than 20 vaccines in clinical development, with five major launches

> planned in the next five years.

>

> The company said it will launch Cervarix for the prevention of HPV

> which causes cervical cancer, Rotarix for rotavirus gastroenteritis,

> Streptorix for pneumococcal disease, an improved flu vaccine and

> Hib-MenCY vaccine combinations against meningitis.

>

> These five products will enter markets that have the potential to

> reach a total market value of $11 billion to $18 billion by 2010,

> Glaxo said.

>

> The company estimates that cumulatively, up to 80 million women could

> be vaccinated by 2010 for protection against cervical cancer, and the

> cervical cancer vaccine market could be valued at $4 billion to $7

> billion per year by 2010. Regulatory filings of Cervarix will take

> place in Europe in the first half of 2006, and in international

> markets during 2006. Discussions on filing with the Food and Drug

> Administration are ongoing in the U.S., where the vaccine has been

> granted " fast track " status.

>

> Glaxo said the launch of its new pediatric vaccines, combined with its

> existing portfolio, will give the company a full range of products to

> meet all infant vaccination schedules in all major markets within the

> first six months of life.

>

> Glaxo estimates that the global market for rotavirus vaccines could be

> valued at $1.8 billion to $2.4 billion by 2010. GSK has submitted

> regulatory filings for Rotarix in Europe and 50 other markets, and

> Rotarix has now been approved in 7 markets, including Mexico.

> Discussions on the U.S. filing are ongoing with the FDA.

>

> Glaxo also said it plans to double its Fluarix manufacturing capacity

> to 80 million doses annually by 2008, is developing an improved flu

> vaccine using a unique adjuvant. The drug maker will develop a new

> cell culture manufacturing process by 2010 to further boost production

> capacity.

>

> Glaxo estimates that the influenza market could more than double from

> its current value to $2.9 billion to $3.7 billion in 2010. Fluarix is

> licensed in 102 countries with 2004 sales of $144 million, and the

> company filed Fluarix with the FDA in May in time to be available for

> the 2005 to 2006 flu season, if it is approved.

>

> Large Phase III trials of the improved flu vaccine are due to start in

> 2006, and regulatory filings will take place in the U.S., Europe and

> international markets in 2008, the company said.

>

> GlaxoKline Biologicals, the company's vaccine manufacturing unit,

> is located in Rixensart, Belgium and posted 2004 sales of nearly $2

> billion. In 2004, GSK Biologicals distributed more than 1.5 billion

> doses of vaccines to 168 countries in both the developed and

> developing world. About 140 million of the doses delivered last year

> were combined pediatric vaccines that protect children against a

> minimum of three and up to six diseases in one vaccine.

>

>

>

>

>

>

>

[Guest guest]

When lobbying our mercury free vaccine act in IL, Glaxo's govt

relations person indicated that they were working to have all of their

vaccines thimerosal free in two years and I believe this new flu

vaccine will have 1.25 micrograms of thimerosal. In my humble

opinion, I think that would be an interesting angle for a journalist

to inquire about. Also, if there is a Senate hearing anyway they can

supeona the scientists who work for the manufacturers to ask at what

level, if any, did they see any adverse effects?

> http://tinyurl.com/9vvpk

>

> ssociated Press

> GlaxoKline to Launch 5 Major Vaccines

> 06.30.2005, 08:47 AM

>

> British drug maker GlaxoKline PLC said Thursday that it has more

> than 20 vaccines in clinical development, with five major launches

> planned in the next five years.

>

> The company said it will launch Cervarix for the prevention of HPV

> which causes cervical cancer, Rotarix for rotavirus gastroenteritis,

> Streptorix for pneumococcal disease, an improved flu vaccine and

> Hib-MenCY vaccine combinations against meningitis.

>

> These five products will enter markets that have the potential to

> reach a total market value of $11 billion to $18 billion by 2010,

> Glaxo said.

>

> The company estimates that cumulatively, up to 80 million women could

> be vaccinated by 2010 for protection against cervical cancer, and the

> cervical cancer vaccine market could be valued at $4 billion to $7

> billion per year by 2010. Regulatory filings of Cervarix will take

> place in Europe in the first half of 2006, and in international

> markets during 2006. Discussions on filing with the Food and Drug

> Administration are ongoing in the U.S., where the vaccine has been

> granted " fast track " status.

>

> Glaxo said the launch of its new pediatric vaccines, combined with its

> existing portfolio, will give the company a full range of products to

> meet all infant vaccination schedules in all major markets within the

> first six months of life.

>

> Glaxo estimates that the global market for rotavirus vaccines could be

> valued at $1.8 billion to $2.4 billion by 2010. GSK has submitted

> regulatory filings for Rotarix in Europe and 50 other markets, and

> Rotarix has now been approved in 7 markets, including Mexico.

> Discussions on the U.S. filing are ongoing with the FDA.

>

> Glaxo also said it plans to double its Fluarix manufacturing capacity

> to 80 million doses annually by 2008, is developing an improved flu

> vaccine using a unique adjuvant. The drug maker will develop a new

> cell culture manufacturing process by 2010 to further boost production

> capacity.

>

> Glaxo estimates that the influenza market could more than double from

> its current value to $2.9 billion to $3.7 billion in 2010. Fluarix is

> licensed in 102 countries with 2004 sales of $144 million, and the

> company filed Fluarix with the FDA in May in time to be available for

> the 2005 to 2006 flu season, if it is approved.

>

> Large Phase III trials of the improved flu vaccine are due to start in

> 2006, and regulatory filings will take place in the U.S., Europe and

> international markets in 2008, the company said.

>

> GlaxoKline Biologicals, the company's vaccine manufacturing unit,

> is located in Rixensart, Belgium and posted 2004 sales of nearly $2

> billion. In 2004, GSK Biologicals distributed more than 1.5 billion

> doses of vaccines to 168 countries in both the developed and

> developing world. About 140 million of the doses delivered last year

> were combined pediatric vaccines that protect children against a

> minimum of three and up to six diseases in one vaccine.

[Guest guest]

As part of their effort for approval they need to hand over

Verstraetenfor, for questioning under oath before congress..

> > http://tinyurl.com/9vvpk

> >

> > ssociated Press

> > GlaxoKline to Launch 5 Major Vaccines

> > 06.30.2005, 08:47 AM

> >

> > British drug maker GlaxoKline PLC said Thursday that it has more

> > than 20 vaccines in clinical development, with five major launches

> > planned in the next five years.

> >

> > The company said it will launch Cervarix for the prevention of HPV

> > which causes cervical cancer, Rotarix for rotavirus gastroenteritis,

> > Streptorix for pneumococcal disease, an improved flu vaccine and

> > Hib-MenCY vaccine combinations against meningitis.

> >

> > These five products will enter markets that have the potential to

> > reach a total market value of $11 billion to $18 billion by 2010,

> > Glaxo said.

> >

> > The company estimates that cumulatively, up to 80 million women could

> > be vaccinated by 2010 for protection against cervical cancer, and the

> > cervical cancer vaccine market could be valued at $4 billion to $7

> > billion per year by 2010. Regulatory filings of Cervarix will take

> > place in Europe in the first half of 2006, and in international

> > markets during 2006. Discussions on filing with the Food and Drug

> > Administration are ongoing in the U.S., where the vaccine has been

> > granted " fast track " status.

> >

> > Glaxo said the launch of its new pediatric vaccines, combined with its

> > existing portfolio, will give the company a full range of products to

> > meet all infant vaccination schedules in all major markets within the

> > first six months of life.

> >

> > Glaxo estimates that the global market for rotavirus vaccines could be

> > valued at $1.8 billion to $2.4 billion by 2010. GSK has submitted

> > regulatory filings for Rotarix in Europe and 50 other markets, and

> > Rotarix has now been approved in 7 markets, including Mexico.

> > Discussions on the U.S. filing are ongoing with the FDA.

> >

> > Glaxo also said it plans to double its Fluarix manufacturing capacity

> > to 80 million doses annually by 2008, is developing an improved flu

> > vaccine using a unique adjuvant. The drug maker will develop a new

> > cell culture manufacturing process by 2010 to further boost production

> > capacity.

> >

> > Glaxo estimates that the influenza market could more than double from

> > its current value to $2.9 billion to $3.7 billion in 2010. Fluarix is

> > licensed in 102 countries with 2004 sales of $144 million, and the

> > company filed Fluarix with the FDA in May in time to be available for

> > the 2005 to 2006 flu season, if it is approved.

> >

> > Large Phase III trials of the improved flu vaccine are due to start in

> > 2006, and regulatory filings will take place in the U.S., Europe and

> > international markets in 2008, the company said.

> >

> > GlaxoKline Biologicals, the company's vaccine manufacturing unit,

> > is located in Rixensart, Belgium and posted 2004 sales of nearly $2

> > billion. In 2004, GSK Biologicals distributed more than 1.5 billion

> > doses of vaccines to 168 countries in both the developed and

> > developing world. About 140 million of the doses delivered last year

> > were combined pediatric vaccines that protect children against a

> > minimum of three and up to six diseases in one vaccine.

[Guest guest]

And how many of them will contain how much mercury?

S S

_______________________________________________

Join Excite! - http://www.excite.com

The most personalized portal on the Web!

[Guest guest]

And I'm sure the long-term, longitudinal safety studies have been

carefully done by independent, unconflicted medical officials.

> http://tinyurl.com/9vvpk

>

> ssociated Press

> GlaxoKline to Launch 5 Major Vaccines

> 06.30.2005, 08:47 AM

>

> British drug maker GlaxoKline PLC said Thursday that it has

more

> than 20 vaccines in clinical development, with five major launches

> planned in the next five years.

>

> The company said it will launch Cervarix for the prevention of HPV

> which causes cervical cancer, Rotarix for rotavirus

gastroenteritis,

> Streptorix for pneumococcal disease, an improved flu vaccine and

> Hib-MenCY vaccine combinations against meningitis.

>

> These five products will enter markets that have the potential to

> reach a total market value of $11 billion to $18 billion by 2010,

> Glaxo said.

>

> The company estimates that cumulatively, up to 80 million women

could

> be vaccinated by 2010 for protection against cervical cancer, and

the

> cervical cancer vaccine market could be valued at $4 billion to $7

> billion per year by 2010. Regulatory filings of Cervarix will take

> place in Europe in the first half of 2006, and in international

> markets during 2006. Discussions on filing with the Food and Drug

> Administration are ongoing in the U.S., where the vaccine has been

> granted " fast track " status.

>

> Glaxo said the launch of its new pediatric vaccines, combined with

its

> existing portfolio, will give the company a full range of products

to

> meet all infant vaccination schedules in all major markets within

the

> first six months of life.

>

> Glaxo estimates that the global market for rotavirus vaccines

could be

> valued at $1.8 billion to $2.4 billion by 2010. GSK has submitted

> regulatory filings for Rotarix in Europe and 50 other markets, and

> Rotarix has now been approved in 7 markets, including Mexico.

> Discussions on the U.S. filing are ongoing with the FDA.

>

> Glaxo also said it plans to double its Fluarix manufacturing

capacity

> to 80 million doses annually by 2008, is developing an improved flu

> vaccine using a unique adjuvant. The drug maker will develop a new

> cell culture manufacturing process by 2010 to further boost

production

> capacity.

>

> Glaxo estimates that the influenza market could more than double

from

> its current value to $2.9 billion to $3.7 billion in 2010. Fluarix

is

> licensed in 102 countries with 2004 sales of $144 million, and the

> company filed Fluarix with the FDA in May in time to be available

for

> the 2005 to 2006 flu season, if it is approved.

>

> Large Phase III trials of the improved flu vaccine are due to

start in

> 2006, and regulatory filings will take place in the U.S., Europe

and

> international markets in 2008, the company said.

>

> GlaxoKline Biologicals, the company's vaccine manufacturing

unit,

> is located in Rixensart, Belgium and posted 2004 sales of nearly $2

> billion. In 2004, GSK Biologicals distributed more than 1.5 billion

> doses of vaccines to 168 countries in both the developed and

> developing world. About 140 million of the doses delivered last

year

> were combined pediatric vaccines that protect children against a

> minimum of three and up to six diseases in one vaccine.

[Guest guest]

Amazing, didn't I just hear or read that big pharma.

was threatening to stop production of vaccines because

of lawsuits????? Lies, lies, lies!

>

>

>

>

____________________________________________________

Sports

Rekindle the Rivalries. Sign up for Fantasy Football

http://football.fantasysports.

[Guest guest]

good lord!

quote:

The company estimates that cumulatively, up to 80

> million women could be vaccinated by 2010 for

protection against cervical cancer...

let's see...tampons contain dioxin.

published scientific reports have shown that evidence

is growing that even low levels of dioxins may be

linked to cancer. moral: we should only use organic

tampons. or we could ignore that and just get the

vaccine.

__________________________________________________